Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren, moxonidine, hydrochlorothiazide, and placebo crossover trial in obesity-related hypertension
2009-015982-29Phase 4Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aliskiren, moxonidine and hydrochlorothiazide in hypertension (HTN), Abdominal adiposity (ABCD) and cardiometabolic risk (CMR), sponsored by University Medical Center Utrecht. Primary endpoints: Endothelial function, Serum adipokine concentrations and 10 more. Started Jun 2010; status: completed.
02
Drugs
aliskirenmoxonidinehydrochlorothiazide
03
Conditions
hypertension (HTN)Abdominal adiposity (ABCD)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2009-015982-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015982-29.